11.10.20

Nicox Initiates Second Phase 3 Trial of NCX 470 in Glaucoma

Source: Nicox

10.26.20

Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Mont Blanc Phase 3 Trial

Source: Nicox

09.24.20

Aerie Pharmaceuticals Announces Interim 90-Day Topline Data From Its 6-Month Mercury 3 Clinical Trial in Europe

Source: Aerie Pharmaceuticals

09.18.20

Study Finds Novel Mechanism That May Confer Protection Against Glaucoma

Source: LSU Health

09.02.20

Nicox Completes Enrollment of the Adaptive Design Cohort of NCX 470 Mont Blanc Phase 3 Glaucoma Trial

Source: Nicox

09.01.20

Injectsense Receives Breakthrough Device Program Designation From FDA for IOP Monitoring System

Source: Injectsense

03.11.20

Reichert Technologies Signs Exclusive Deal for CATS Reusable Tonometer Prisms

Source: Reichert Technologies

01.02.20

Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda Marketing Authorization Application in Europe

Source: Aerie Pharmaceuticals

11.05.19

Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil in Phase 2 Study Conducted in Japan

Source: Aerie Pharmaceuticals

10.11.19

Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in US IDE Trial for iStent infinite

Source: Glaukos

View more stories